Kalkine has a fully transformed New Avatar.
Last update at 2025-07-09T00:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
Wed 26 Jul 23, 10:00 AMOpthea to Present at the 2023 Ophthalmology Innovation Summit
Mon 24 Jul 23, 10:00 AMOpthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
Thu 13 Jul 23, 10:00 AMOpthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
Mon 10 Jul 23, 10:00 AMOpthea Appoints Anshul Thakral as Non-Executive Director of the Board
Thu 08 Jun 23, 10:00 AMOpthea to Present at the Jefferies 2023 Healthcare Conference
Thu 25 May 23, 10:00 AMOpthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
Wed 17 May 23, 10:00 AMOpthea To Present at the JMP Securities Life Sciences Conference
Mon 08 May 23, 09:30 AMBreakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Income before tax | -148.44744M | -99.11666M | -50.28334M | -17.22088M | -24.89497M |
Minority interest | - | - | - | - | - |
Net income | -142.52108M | -92.81737M | -45.34450M | -11.35760M | -14.64413M |
Selling general administrative | 27.84M | 17.83M | 13.72M | 4.00M | 3.07M |
Selling and marketing expenses | - | - | - | - | 0.29M |
Gross profit | 0.11M | 0.09M | 0.07M | -0.45620M | -0.11488M |
Reconciled depreciation | 0.10M | 0.08M | 0.11M | 0.14M | 0.03M |
Ebit | -146.79830M | -93.72380M | -28.62855M | -17.20638M | -25.98888M |
Ebitda | -146.69707M | -93.64542M | -28.52189M | -17.10742M | -25.96570M |
Depreciation and amortization | 0.10M | 0.08M | 0.11M | 0.10M | 0.02M |
Non operating income net other | - | - | - | - | - |
Operating income | -146.79830M | -93.72380M | -28.62855M | -17.20638M | -25.98888M |
Other operating expenses | 150.13M | 96.63M | 39.71M | 17.48M | 25.73M |
Interest expense | 13.46M | 0.24M | 21.65M | 0.01M | 1.09M |
Tax provision | -5.92635M | -6.29929M | -4.93885M | -8.53312M | -14.63697M |
Interest income | 1.58M | 0.24M | 0.37M | 0.32M | 1.12M |
Net interest income | -10.23466M | 0.24M | 0.37M | 0.72M | 0.76M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -5.92635M | -6.29929M | -4.93885M | -5.86328M | -10.25084M |
Total revenue | 0.11M | 0.09M | 0.07M | 0.09M | 0.16M |
Total operating expenses | 150.13M | 96.63M | 39.71M | 17.48M | 25.73M |
Cost of revenue | 0.17M | 0.16M | 0.43M | 0.54M | 0.27M |
Total other income expense net | 11.81M | -5.39286M | -21.65479M | -0.01449M | 1.09M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -142.52108M | -92.81737M | -45.34450M | -16.52928M | -20.91006M |
Net income applicable to common shares | -142.52109M | -92.81737M | -45.34450M | -16.52928M | -20.91006M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
Total assets | 188.79M | 98.64M | 60.05M | 138.41M | 49.40M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | - | - | 8.72M | 14.39M | 6.19M |
Total liab | 264.60M | 104.40M | 12.07M | 3.12M | 4.86M |
Total stockholder equity | -75.81008M | -5.75855M | 47.98M | 135.29M | 44.53M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 24.84M | 0.75M | 0.64M | 0.58M | 0.16M |
Common stock | 466.08M | 320.88M | 235.28M | 234.15M | 111.38M |
Capital stock | 466.08M | 320.88M | 235.28M | 234.15M | 111.38M |
Retained earnings | -579.70454M | -359.36781M | -216.94135M | -124.12398M | -70.49118M |
Other liab | - | 0.00763M | 0.03M | 0.02M | 0.04M |
Good will | - | - | - | - | - |
Other assets | - | 0.05M | 0.11M | 0.17M | 0.00000M |
Cash | 172.47M | 89.19M | 44.63M | 118.19M | 42.62M |
Cash and equivalents | - | 77.12M | 32.78M | 102.65M | 40.57M |
Total current liabilities | 64.06M | 18.65M | 12.04M | 3.11M | 4.75M |
Current deferred revenue | 1.06M | - | - | - | 0.48M |
Net debt | -30.82366M | -89.00700M | -44.63129M | -118.08021M | -42.43330M |
Short term debt | 0.09M | 0.10M | 0.00000M | 0.11M | 0.10M |
Short long term debt | - | - | - | - | - |
Short long term debt total | 141.65M | 0.18M | - | 0.11M | 0.18M |
Other stockholder equity | - | 20.09M | 29.64M | 25.26M | 9.50M |
Property plant equipment | - | 0.20M | 0.03M | 0.12M | 0.28M |
Total current assets | 188.19M | 98.39M | 59.91M | 138.12M | 49.00M |
Long term investments | - | - | - | 0.00000M | 0.29M |
Net tangible assets | - | -5.85318M | 47.98M | 135.29M | 64.81M |
Short term investments | - | - | - | - | - |
Net receivables | 11.82M | 6.56M | 6.56M | 5.54M | 0.20M |
Long term debt | 141.55M | 85.66M | - | - | - |
Inventory | - | - | - | - | - |
Accounts payable | 38.06M | 17.80M | 11.40M | 2.42M | 4.01M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 37.81M | 32.73M | 29.64M | 25.26M | 3.64M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | 162.10M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 0.47M | 0.05M | 0.11M | 0.17M | 0.00000M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 0.60M | 0.26M | 0.14M | 0.29M | 0.39M |
Capital lease obligations | 0.09M | 0.18M | 0.00000M | 0.11M | 0.27M |
Long term debt total | - | 85.74M | 0.00000M | 0.00000M | 0.12M |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Investments | -0.02195M | -0.01691M | 0.67M | 0.48M | 0.34M |
Change to liabilities | 7.30M | 8.51M | -1.55244M | -0.05691M | -1.42798M |
Total cashflows from investing activities | -0.02195M | -0.01691M | 0.66M | 0.48M | 0.32M |
Net borrowings | 84.43M | -0.08558M | -0.08737M | -0.10019M | -0.10019M |
Total cash from financing activities | 248.70M | 0.24M | 156.76M | 48.98M | 12.63M |
Change to operating activities | 6.28M | 5.85M | -14.19104M | 0.06M | -0.06685M |
Net income | -211.88068M | -127.99021M | -60.78802M | -16.52928M | -20.91006M |
Change in cash | 69.08M | -92.52939M | 95.41M | 40.49M | -10.97531M |
Begin period cash flow | 64.90M | 157.43M | 62.02M | 21.53M | 32.51M |
End period cash flow | 133.99M | 64.90M | 157.43M | 62.02M | 21.53M |
Total cash from operating activities | -179.30389M | -98.36710M | -61.05838M | -8.78227M | -24.18516M |
Issuance of capital stock | 81.82M | 0.00000M | 105.48M | 33.72M | 8.85M |
Depreciation | 0.15M | 0.11M | 0.14M | 0.14M | 0.03M |
Other cashflows from investing activities | - | 0.00000M | 0.67M | 0.48M | 0.34M |
Dividends paid | - | - | - | - | - |
Change to inventory | - | - | - | - | - |
Change to account receivables | 0.56M | 0.42M | -0.49563M | 0.01M | 0.10M |
Sale purchase of stock | 167.36M | 0.26M | 117.02M | 49.08M | 12.63M |
Other cashflows from financing activities | -0.03454M | -0.03243M | -0.02976M | -0.03341M | 12.63M |
Change to netincome | 7.86M | 6.74M | 15.80M | 7.58M | -1.91131M |
Capital expenditures | 0.03M | 0.02M | 0.02M | 0.00724M | 0.02M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | 20.75M | 20.22M | -21.60105M | 0.02M | -1.39688M |
Stock based compensation | 5.83M | 5.25M | 3.90M | 0.73M | 0.97M |
Other non cash items | 11.77M | 10.34M | 22.23M | 12.56M | -1.91131M |
Free cash flow | -179.33653M | -98.39042M | -61.07541M | -8.78951M | -24.20323M |
Sector: Healthcare Industry: Biotechnology
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
OPT Opthea Ltd |
- -% | 0.60 | - | 6.75 | 3537.08 | 4.21 | 5781.33 | -1.0623 |
CSL CSL Ltd |
-1.49 0.61% | 240.92 | 28.85 | 32.79 | 7.69 | 4.14 | 5.94 | 18.43 |
TLX Telix Pharmaceuticals Ltd |
-0.38 1.55% | 24.09 | 163.67 | 47.85 | 10.52 | 14.41 | 10.29 | 87.11 |
MSB Mesoblast Ltd |
0.01 0.61% | 1.66 | - | 454.55 | 369.57 | 2.96 | 67.90 | -9.8623 |
NEU Neuren Pharmaceuticals Ltd |
-0.04 0.27% | 14.57 | 13.39 | 35.21 | 8.48 | 5.06 | 7.81 | 9.49 |
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
650 Chapel Street, South Yarra, VIC, Australia, 3141
Name | Title | Year Born |
---|---|---|
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | MD, CEO & Exec. Director | 1974 |
Ms. Judith J. Robertson B.A., M.B.A. | Chief Commercial Officer | 1960 |
Dr. Joel Naor M.D., MBA, MSc | Chief Medical Officer | NA |
Ms. Karen Adams CPA | VP of Fin. & Company Sec. | 1971 |
Mr. Timothy E. Morris CPA, CPA | Chief Financial Officer | 1961 |
Ms. Annie Lee | Fin. & Operations Mang. | NA |
Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing & Controls Devel. | 1964 |
Mr. Bruno Gagnon BPHARM, M.Sc. | Sr. VP of Global Clinical Operations | NA |
Dr. Ian Leitch | Director of Clinical Research | 1963 |
Dr. James Goding | Independent Consultant | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.